×
About 7,574 results

ALLMedicine™ Vitiligo Center

Research & Reviews  3,663 results

Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.
https://doi.org/10.1080/08916934.2020.1836489
Autoimmunity Al Robaee AA, Alzolibani AA et. al.

Oct 21st, 2020 - Regulation of melanogenesis by tyrosinase has now become an attractive approach for treatment of vitiligo but still the role of tyrosinase in the induction of depigmentation remains largely unexplored. This study was explored the role of tyrosinas...

Clinical Observation on Therapeutic Effect of Filiform Fire Needle for Vitiligo: A Retr...
https://doi.org/10.1111/dth.14415
Dermatologic Therapy; Huang M, Tang L et. al.

Oct 16th, 2020 - Vitiligo is a common and refractory disease worldwide. The limited efficiency and side effects of the conventional treatment options create demands towards the development of strategies. Excellent repigmentation is demonstrated after several filif...

Vitexin protects melanocytes from oxidative stress via activating MAPK-Nrf2/ARE pathway.
https://doi.org/10.1080/08923973.2020.1835952
Immunopharmacology and Immunotoxicology; Li XS, Tang XY et. al.

Oct 13th, 2020 - Introduction: Vitiligo is the most common type of depigmented skin disease. Cellular oxidative stress caused by reactive oxygen species (ROS) has been implicated in the pathogenesis of vitiligo. Nuclear factor E2-related factor 2 (Nrf2)/antioxidan...

A rare case of coexistence of autoimmune polyglandular syndrome type 3 with growth horm...
https://doi.org/10.1177/0300060520961684
The Journal of International Medical Research; Zhou W, Lin H et. al.

Oct 13th, 2020 - Autoimmune polyglandular syndrome (APS) is a rare disease that is characterized by autoimmune reactions to multiple endocrine and non-endocrine organs, which can be divided into four main types. The principal manifestations of APS-3 are autoimmune...

Type I interferon signaling limits viral vector priming of CD8+ T cells during initiati...
https://doi.org/10.1111/pcmr.12935
Pigment Cell & Melanoma Research; Riding RL, Richmond JM et. al.

Oct 11th, 2020 - Vitiligo is an autoimmune skin disease in which epidermal melanocytes are targeted for destruction by CD8+ T cells specific for melanocyte/melanoma-shared antigens. IFNγ is the central cytokine driving disease but the role of type I IFN in vitilig...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of vitiligo in Japan.
https://doi.org/10.1111/1346-8138.12099
The Journal of Dermatology; Oiso N, Suzuki T et. al.

Feb 27th, 2013 - Vitiligo is an acquired pigment disorder in which depigmented macules result from the loss of melanocytes from the involved regions of skin and hair. The color dissimilarity on the cosmetically sensitive regions frequently induces quality of life ...

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 6th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

Guideline for the diagnosis and management of vitiligo.
https://doi.org/10.1111/j.1365-2133.2008.08881.x
The British Journal of Dermatology; Gawkrodger DJ, Ormerod AD et. al.

Nov 27th, 2008 - This detailed and user-friendly guideline for the diagnosis and management of vitiligo in children and adults aims to give high quality clinical advice, based on the best available evidence and expert consensus, taking into account patient choice ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  3,703 results

Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.
https://doi.org/10.1080/08916934.2020.1836489
Autoimmunity Al Robaee AA, Alzolibani AA et. al.

Oct 21st, 2020 - Regulation of melanogenesis by tyrosinase has now become an attractive approach for treatment of vitiligo but still the role of tyrosinase in the induction of depigmentation remains largely unexplored. This study was explored the role of tyrosinas...

Clinical Observation on Therapeutic Effect of Filiform Fire Needle for Vitiligo: A Retr...
https://doi.org/10.1111/dth.14415
Dermatologic Therapy; Huang M, Tang L et. al.

Oct 16th, 2020 - Vitiligo is a common and refractory disease worldwide. The limited efficiency and side effects of the conventional treatment options create demands towards the development of strategies. Excellent repigmentation is demonstrated after several filif...

Vitexin protects melanocytes from oxidative stress via activating MAPK-Nrf2/ARE pathway.
https://doi.org/10.1080/08923973.2020.1835952
Immunopharmacology and Immunotoxicology; Li XS, Tang XY et. al.

Oct 13th, 2020 - Introduction: Vitiligo is the most common type of depigmented skin disease. Cellular oxidative stress caused by reactive oxygen species (ROS) has been implicated in the pathogenesis of vitiligo. Nuclear factor E2-related factor 2 (Nrf2)/antioxidan...

A rare case of coexistence of autoimmune polyglandular syndrome type 3 with growth horm...
https://doi.org/10.1177/0300060520961684
The Journal of International Medical Research; Zhou W, Lin H et. al.

Oct 13th, 2020 - Autoimmune polyglandular syndrome (APS) is a rare disease that is characterized by autoimmune reactions to multiple endocrine and non-endocrine organs, which can be divided into four main types. The principal manifestations of APS-3 are autoimmune...

Type I interferon signaling limits viral vector priming of CD8+ T cells during initiati...
https://doi.org/10.1111/pcmr.12935
Pigment Cell & Melanoma Research; Riding RL, Richmond JM et. al.

Oct 11th, 2020 - Vitiligo is an autoimmune skin disease in which epidermal melanocytes are targeted for destruction by CD8+ T cells specific for melanocyte/melanoma-shared antigens. IFNγ is the central cytokine driving disease but the role of type I IFN in vitilig...

see more →

News  183 results

Dermatology therapies evolve as disease knowledge and investment grow
https://www.mdedge.com/dermatology/article/219314/medical-dermatology/dermatology-therapies-evolve-disease-knowledge-and/page/0/2?channel=27980

Mar 19th, 2020 - Spillover to other diseases JAK inhibitors – some in oral and some in topical form – are showing efficacy in ongoing research for alopecia areata (AA) and vitiligo as well, Dr. Blauvelt said.

Vitiligo tied to lower risk of internal malignancies
https://www.mdedge.com/dermatology/article/217491/pigmentation-disorders/vitiligo-tied-lower-risk-internal-malignancies?channel=39313
Bruce Jancin

Feb 19th, 2020 - LAHAINA, HAWAII – Individuals with vitiligo demonstrated a markedly reduced rate of internal malignancies in a recent first-of-its-kind “big data” study from South Korea, Iltefat Hamzavi, MD, said at the Hawaii Dermatology Seminar provided by Glob.

Pembrolizumab-Induced Lobular Panniculitis in the Setting of Metastatic Melanoma
https://www.mdedge.com/dermatology/article/216730/melanoma/pembrolizumab-induced-lobular-panniculitis-setting-metastatic?channel=44
Caitlin M. Peterman, MD, Leslie Robinson-Bostom, MD et. al.

Feb 5th, 2020 - To the Editor: Pembrolizumab is an anti–programmed death receptor 1 humanized monoclonal antibody used for treating advanced or metastatic melanoma. 1 It is associated with several immune-related adverse events because it blocks a T-cell receptor c.

New Barbie lineup includes a doll with vitiligo
https://www.mdedge.com/dermatology/article/216596/pigmentation-disorders/new-barbie-lineup-includes-doll-vitiligo?channel=27980
Doug Brunk

Feb 3rd, 2020 - A new line of Barbie dolls unveiled by Mattel earlier this month includes one with vitiligo, much to the delight of clinicians who treat children and adolescents with the condition. Mattel, Inc.

Vitiligo: First-ever RCT is smashing success
https://www.mdedge.com/dermatology/article/211169/pigmentation-disorders/vitiligo-first-ever-rct-smashing-success?channel=29134
Bruce Jancin

Oct 29th, 2019 - MADRID – Repigmentation in patients with vitiligo documented at 24 weeks continued to increase up to 1 year, in a randomized clinical trial of ruxolitinib cream for the treatment of vitiligo, Amit G. Pandya, MD, reported at the annual congress of.

see more →

Patient Education  19 results see all →